Canopy Growth Corp (TSE:WEED) Expands European Footprint With Significant Czech Republic Deal


Canopy Growth Corp (TSE:WEED) (OTCMKTS:TWMJF) (FRA:11L1) European growth strategy rose to another level today.

The company signed definitive agreements to acquire Annabis Medical s.r.o, expanding the Company’s focus into another emerging medical cannabis market. Annabis Medical is the purported leader in the Czech Republic’s medical cannabis industry. They currently import and distribute cannabis products pursuant to federal Czech licenses, with products for sale through pharmacy channels across the Czech Republic. Its founder and CEO, Dr. Robin Kazík, will stay on and continue to operate the Czech subsidiary on Canopy’s behalf.

Ultimately, the acquisition will allow Canopy Growth to bring its formidable Spectrum Cannabis brand to another European market.

The acquisition of Annabis Medical—expected to close April 16—builds on the company’s leadership position in the European medical cannabis space. Previously, Canopy Growth inked a partnership and supply agreement with Spanish pharmaceutical leader Alcaliber S.A. Furthermore, Canopy Growth already operates in the German market through its subsidiary, Spektrum Cannabis GmbH, and has formed a partnership, Spectrum Cannabis Denmark ApS, which is licensed to cultivate cannabis in a 40,000 square meter greenhouse production facility located in Odense, Denmark. These assets—combined with Canopy Growth’s unparalleled Canadian production and sales platforms—represent the world’s largest and most diversified cannabis platform.

With their move into the Czech Republic, Canopy notches another jurisdictional win under their belt. By our count, the company now operates in at least 8 countries worldwide (including Canada); a number which is sure to increase as cannabis obtains legal status at an astounding rate. Given that president Trump promised a leading Senate Republican that he will support congressional efforts to protect states that have legalized marijuana, the United States may soon follow.

The full list of Canopy Growth controlled or jointly-controlled subsidiaries and affiliate investments operating internationally is as follows:

Legal entity Defined as % Ownership Country Of Operation
Spektrum Cannabis GmbH Spektrum Cannabis 100 Germany
Spectrum Chile SpA Spectrum Chile 85 Chile
Grow House JA Limited Tweed JA 49 Jamaica
Spectrum Cannabis Denmark Aps Spectrum Cannabis Denmark 62 Denmark
Annabis Medical s.r.o Annabis Medical Czech Republic
Affiliate Investments
Legal entity Defined as % Ownership Country Of Operation
Bedrocan Brasil S.A. Bedrocan Brasil 39.4 Brazil
Entourage Phytolab S.A Entourage 38.5 Brazil
AusCann Group Holdings Ltd. AusCann 11 Australia
Vapium Incorporated Vapium 12.2 Online Retail


Under the terms of the Annabis Medical agreement, Canopy will issue Dr. Kazík 50,735 common shares in the capital of the Company valued at $1,491,882.70 on closing and, subject to meeting certain milestones, will issue up to an additional 34,758 common shares valued at $1,022,080.00, based on the 5-day VWAP of $29.40519 on April 5, 2018. The total value of the consideration payable under the terms of the agreement is approximately $2,513,962.70 CAD.

Previously, Canopy Growth CEO stopped by the Midas Letter studios to talk about the company international growth strategy.

Bruce Linton shed light on why Canopy Growth Corp is likely to continue on its astonishing growth trajectory as he strives for global domination through the deployment of an international cannabis industry strategy.

The acquisition of Annabis Medical makes clear that the international arms race between Canadian cannabis conglomerates is on.  On April 13, Aurora Cannabis Inc (TSE:ACB) (OTCQB:ACBFF) (FRA:21P) upped the ante by announcing the successful delivery of the first ever batch of privately exported medical cannabis from Canada to the Italian government.

We certainly don’t expect this trend to abate anytime soon.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.